AS­CO ab­stracts mint some ear­ly win­ners, but Io­vance, Spring­Works get hit by mas­sive loss­es

Be­fore can­cer-fo­cused biotechs start their trek to the first in-per­son Amer­i­can So­ci­ety of Clin­i­cal On­col­o­gy (AS­CO) an­nu­al con­fer­ence since the pan­dem­ic be­gan, in­vestors have tak­en …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER